1. Home
  2. BANL vs SABS Comparison

BANL vs SABS Comparison

Compare BANL & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

HOLD

Current Price

$0.46

Market Cap

11.7M

Sector

Energy

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.91

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANL
SABS
Founded
2015
2014
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7M
181.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
BANL
SABS
Price
$0.46
$3.91
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.00
AVG Volume (30 Days)
35.7K
303.1K
Earning Date
09-04-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$580,456,800.00
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.38
N/A
52 Week Low
$0.40
$1.00
52 Week High
$1.30
$6.60

Technical Indicators

Market Signals
Indicator
BANL
SABS
Relative Strength Index (RSI) 46.73 56.66
Support Level $0.42 $3.54
Resistance Level $0.48 $4.03
Average True Range (ATR) 0.02 0.28
MACD 0.01 -0.02
Stochastic Oscillator 64.15 76.92

Price Performance

Historical Comparison
BANL
SABS

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: